Stoke Therapeutics boosts a protein linked to inherited blindness, but can STK-002 save vision?
Stoke Therapeutics reports STK-002 OPA1 protein gains as Phase 1 OSPREY advances. Examine the evidence, safety questions and 2027 readout.
Pharma & Biotech
Pharma & Biotech
Stoke and Biogen report four-year zorevunersen data showing durable Dravet seizure reductions
Stoke Therapeutics and Biogen say four-year zorevunersen data show durable seizure reductions plus continuing cognitive and behavioral improvements as Phase 3 EMPEROR advances.